Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection

Introduction Chronic hepatitis B (CHB) virus (HBV) infection has emerged as a global health burden affecting nearly 292 million people. Tenofovir alafenamide (TAF) is an effective treatment for CHB patients. However, the detailed mechanism underlying the antiviral activity of TAF remains unclear. Methods In this study, we investigated the antiviral effect of exosomes derived from the serum of CHB patients treated with TAF (Exo-serum) and TAF-treated macrophages (MP) (Exo-MP(TAF)). Results RNAseq analysis was also performed to determine the associated long non-coding RNAs (lncRNAs). The results demonstrated that both Exo-serum and Exo-MP(TAF) could be taken up by HepAD38 cells and exhibited potent antiviral activities, as manifested by significantly downregulating the levels of hepatitis B surface antigen, hepatitis B e antigen, HBV DNA, and covalently closed circular DNA. The antiviral effect of Exo-serum was more potent than those of TAF treatment alone. RNAseq analysis revealed that lncRNA HOTTIP was upregulated significantly in Exo-serum. Further, lncRNA HOTTIP knockdown reversed the antiviral effect of Exo-MP(TAF) on HepAD38 cells, whereas lncRNA HOTTIP knockdown exerted the opposite roles. Discussion Taken together, these results suggest that exosomal lncRNA HOTTIP is essential for the antiviral activity of TAF and provide a novel understanding of the exosome-mediated mechanism underlying HBV infection.

[1]  Jiezuan Yang,et al.  Exosomes in Hepatitis B Virus Transmission and Related Immune Response. , 2020, The Tohoku journal of experimental medicine.

[2]  M. Kretz,et al.  From structure to function: Route to understanding lncRNA mechanism , 2020, BioEssays : news and reviews in molecular, cellular and developmental biology.

[3]  Juan Chen,et al.  LncRNA HOTAIR Modulates Hepatitis B Virus Transcription and Replication by Enhancing SP1 Transcription Factor. , 2020, Clinical science.

[4]  Q. Ning,et al.  Exosomes with miR-574 transfer anti-HBV activity mediated by the interferon from macrophage to HBV-infected hepatocyte. , 2020, The Journal of infectious diseases.

[5]  H. Nomura,et al.  Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[6]  Jie Yuan,et al.  lncRNA-CD160 decreases the immunity of CD8+ T cells through epigenetic mechanisms in hepatitis B virus infection , 2020, Oncology letters.

[7]  B. Cowie,et al.  Global Hepatitis B Virus Elimination by 2030: China Is Pivotal and Instructive. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Exosome , 2020, Definitions.

[9]  K. Blennow,et al.  Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate , 2019, PloS one.

[10]  M. Nakao,et al.  Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate , 2019, Journal of medical virology.

[11]  Hongwei Gao,et al.  LncRNA PCNAP1 modulates hepatitis B virus replication and enhances tumor growth of liver cancer , 2019, Theranostics.

[12]  Q. Ning,et al.  Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study , 2019, Hepatology International.

[13]  Limin Chen,et al.  Exosomes Modulate the Viral Replication and Host Immune Responses in HBV Infection , 2019, BioMed research international.

[14]  Wei Liu,et al.  Three isoforms of exosomal circPTGR1 promote hepatocellular carcinoma metastasis via the miR449a–MET pathway , 2019, EBioMedicine.

[15]  Zhenghong Yuan,et al.  Exosomes Exploit the Virus Entry Machinery and Pathway To Transmit Alpha Interferon-Induced Antiviral Activity , 2018, Journal of Virology.

[16]  M. Buti,et al.  No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection , 2018, Antimicrobial Agents and Chemotherapy.

[17]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[18]  Ronghua Li,et al.  [Expression profiles of the exosomal miRNAs in the chronic hepatitis B patients with persistently normal ALT]. , 2018, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[19]  Ç. Biray Avcı,et al.  Analysis of long non-coding RNA (lncRNA) expression in hepatitis B patients. , 2018, Bosnian journal of basic medical sciences.

[20]  G. Calin,et al.  Exosomal lncRNAs as new players in cell-to-cell communication. , 2018, Translational cancer research.

[21]  Q. Ning,et al.  Altered expression of interferon‐stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection , 2017, Antiviral research.

[22]  P. Robbins,et al.  Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes , 2017, Scientific Reports.

[23]  N. Xia,et al.  Detection of HBV Covalently Closed Circular DNA , 2017, Viruses.

[24]  D. Durantel.  New treatments to reach functional cure: Virological approaches. , 2017, Best practice & research. Clinical gastroenterology.

[25]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[26]  M. Kohara,et al.  Extracellular Vesicles Including Exosomes Regulate Innate Immune Responses to Hepatitis B Virus Infection , 2016, Front. Immunol..

[27]  J. Ioannidis,et al.  Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis , 2016, Molecular Cancer.

[28]  K. Tashima,et al.  Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results , 2016, Journal of acquired immune deficiency syndromes.

[29]  J. Kao,et al.  Hepatitis B virus: new therapeutic perspectives , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[30]  K. Ishii,et al.  [Epidemiology of hepatitis A virus]. , 2015, Nihon rinsho. Japanese journal of clinical medicine.

[31]  M. Alenquer,et al.  Exosome Biogenesis, Regulation, and Function in Viral Infection , 2015, Viruses.

[32]  D. Podzamczer,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials , 2015, The Lancet.

[33]  Alexander J. Federation,et al.  RNA Exosome-Regulated Long Non-Coding RNA Transcription Controls Super-Enhancer Activity , 2015, Cell.

[34]  Feng Xie,et al.  Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV , 2015, Tumor Biology.

[35]  H. Ishwaran,et al.  Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways , 2014, Cell.

[36]  U. Bredeek,et al.  Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults , 2013, Journal of acquired immune deficiency syndromes.

[37]  Jiangxia Liu,et al.  Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity , 2013, Nature Immunology.

[38]  M. Dehesa-Violante,et al.  Epidemiology of hepatitis virus B and C. , 2007, Archives of medical research.

[39]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[40]  A. Lok.  Hepatitis B Treatment: What We Know Now and What Remains to Be Researched , 2019 .

[41]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[42]  Maire Peters,et al.  Comparison of serum exosome isolation methods for microRNA profiling. , 2014, Clinical biochemistry.

[43]  John R. Williams.  DECLARATION OF HELSINKI , 1964 .